- Home
- ALTO vs TNYA Comparison
ALTO vs TNYA Comparison
Compare ALTO & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALTO | TNYA |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.1M | 157.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ALTO | TNYA |
|---|---|---|
| Price | $2.72 | $0.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $5.50 | $5.25 |
| AVG Volume (30 Days) | 864.9K | ★ 3.9M |
| Earning Date | 03-04-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $922,309,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.76 | $0.36 |
| 52 Week High | $3.18 | $2.35 |
Technical Indicators
Market Signals| Indicator | ALTO | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 48.21 | 46.77 |
| Support Level | $2.51 | $0.75 |
| Resistance Level | $2.85 | $0.94 |
| Average True Range (ATR) | 0.21 | 0.07 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 28.31 | 39.60 |
Price Performance
Historical ComparisonAbout ALTO Alto Ingredients Inc.
Alto Ingredients Inc is a producer of specialty alcohols and essential ingredients. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include food and beverage companies and consumer products manufacturers and distributors. The company operates under four segments: Marketing and distribution, Pekin Campus production, Western production, and Corporate.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.